Medicines – Fabrica De Cosas http://fabricadecosas.org/ Thu, 25 Nov 2021 05:40:43 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://fabricadecosas.org/wp-content/uploads/2021/10/icon-23-70x70.png Medicines – Fabrica De Cosas http://fabricadecosas.org/ 32 32 Center to introduce a new law; All you need to know https://fabricadecosas.org/center-to-introduce-a-new-law-all-you-need-to-know/ Thu, 25 Nov 2021 05:40:43 +0000 https://fabricadecosas.org/center-to-introduce-a-new-law-all-you-need-to-know/ Online sales of drugs, also known as e-pharmacies, are currently unregulated and their existence is constantly challenged by traditional chemists. Representation image. Image courtesy: Unsplash @ hikendal A new law could legalize electronic pharmacies in the country, as provisions relating to the use of information technology in the distribution, manufacture and sale of drugs are […]]]>

Online sales of drugs, also known as e-pharmacies, are currently unregulated and their existence is constantly challenged by traditional chemists.

Representation image. Image courtesy: Unsplash @ hikendal

A new law could legalize electronic pharmacies in the country, as provisions relating to the use of information technology in the distribution, manufacture and sale of drugs are envisaged in a bill, News18.com has learned.

The expert group formed by the Modi government to draft laws on drugs, cosmetics and medical devices is ready to submit the draft document by November 30.

Currently, the industry is governed by the Drugs and Cosmetics Act 1940 which regulates the import, manufacture, distribution and sale of drugs and cosmetics.

In September, News18.com reported that the government had formed an eight-member group, led by India’s Comptroller General of Drugs, VG Somani, to review the country’s drug laws.

Previously, there was no provision on the use of technology in the sale, manufacture and distribution of drugs, as laws were developed long before the advent and use of these services, in 1940.

“The draft document will contain a section on IT provisions. We are in the final stage of finalizing the document and will submit it by the end of this month within the allotted time, ”said a government official familiar with the matter.

One of the biggest advantages of including IT provisions in the new laws is that they could additionally be used to legalize the online sale of medicines in India.

Considering that online sales of drugs, also known as e-pharmacies, are currently unregulated, their existence is constantly met with opposition from mainstream chemists.

Due to the lack of clear laws, e-pharmacies function as marketplaces and serve patients as a platform to order drugs from vendors who adhere to the law and rules on drugs and cosmetics.

“Although the draft document does not talk about online sales in particular, the rules can be formed using the computer provisions of the document for online pharmacies.”

The panel held several meetings with stakeholders before starting the process of writing the first draft.

The panel also took into account suggestions from the Bureau of Narcotics, followed by meetings with drug regulators across India. Consumer groups, associations of chemists, drug manufacturers and contract research organizations (CROs) were also consulted.


Source link

]]>
Long-Term Use of Immunosuppressive Drugs and Hospital Outcomes of COVID-19: A Retrospective Cohort Study Using Data from the National COVID Cohort Collaborative https://fabricadecosas.org/long-term-use-of-immunosuppressive-drugs-and-hospital-outcomes-of-covid-19-a-retrospective-cohort-study-using-data-from-the-national-covid-cohort-collaborative/ Mon, 22 Nov 2021 06:00:00 +0000 https://fabricadecosas.org/long-term-use-of-immunosuppressive-drugs-and-hospital-outcomes-of-covid-19-a-retrospective-cohort-study-using-data-from-the-national-covid-cohort-collaborative/ This article was originally published here Lancet Rheumatol. November 15, 2021. doi: 10.1016 / S2665-9913 (21) 00325-8. Online ahead of print. ABSTRACT BACKGROUND: Many people take long-term immunosuppressive drugs. We evaluated whether these people perform worse when hospitalized with COVID-19 compared to people who are not immunocompromised. METHODS: We conducted a retrospective cohort study using […]]]>

This article was originally published here

Lancet Rheumatol. November 15, 2021. doi: 10.1016 / S2665-9913 (21) 00325-8. Online ahead of print.

ABSTRACT

BACKGROUND: Many people take long-term immunosuppressive drugs. We evaluated whether these people perform worse when hospitalized with COVID-19 compared to people who are not immunocompromised.

METHODS: We conducted a retrospective cohort study using data from the National COVID Cohort Collaborative (N3C), the largest longitudinal repository of electronic health records of hospitalized patients with confirmed or suspected COVID-19 in the United States, between the January 1, 2020 and June 11, 2021, within 42 healthcare systems. We compared adults with immunosuppressive drugs used before admission to adults without long-term immunosuppression. We looked at immunosuppression as a whole, as well as by 15 drug classes and three main indications for immunosuppressive drugs. We used the Fine and Gray proportional underdistribution risk models to estimate the risk ratio (HR) for the risk of invasive mechanical ventilation, with the concurrent risk of death. We used Cox proportional hazards models to estimate RHs for hospital deaths. The models were fitted using a doubly robust propensity score methodology.

RESULTS: Among the 231,830 adults potentially eligible in the N3C standard who were admitted to hospital with confirmed or suspected COVID-19 during the study period, 222,575 met the inclusion criteria (mean age 59 years [SD 19]; 111,269 [50%] Male). The most common comorbidities were diabetes (23%), lung disease (17%) and kidney disease (13%). 16,494 (7%) patients had long-term immunosuppression with drugs for various conditions, including rheumatologic disease (33%), solid organ transplants (26%) or cancer (22%). In the propensity score-matched cohort (comprising 12,841 immunocompromised patients and 29,386 non-immunocompromised patients), immunosuppression was associated with a reduced risk of invasive ventilation (HR 0.89, 95% CI 0.83-0, 96) and there was no overall association between long-term immunosuppression and the risk of hospital death. None of the 15 drug classes examined was associated with an increased risk of invasive mechanical ventilation. Although there was no statistically significant association between most drugs and hospital deaths, increases were seen with rituximab for rheumatologic disease (1.72, 1.10-2 , 69) and for cancer (2.57, 1.86-3 · 56). Results were generally consistent between subgroup analyzes that considered race and ethnicity or gender, as well as between sensitivity analyzes that varied exposure, covariates, and outcome definitions.

INTERPRETATION: Among this cohort, with the exception of rituximab, there was no increased risk of mechanical ventilation or in-hospital death for the rheumatologic, antineoplastic or antimetabolite therapies examined.

FUNDING: None.

IDPM: 34806036 | PMC: PMC8592562 | DOI: 10.1016 / S2665-9913 (21) 00325-8


Source link

]]>
How the UAE took action against fake vaccinations against Covid, drugs sold on social media – News https://fabricadecosas.org/how-the-uae-took-action-against-fake-vaccinations-against-covid-drugs-sold-on-social-media-news/ Sun, 21 Nov 2021 14:12:10 +0000 https://fabricadecosas.org/how-the-uae-took-action-against-fake-vaccinations-against-covid-drugs-sold-on-social-media-news/ Avoid buying drugs or supplements online, health ministry official warns Dr Amin Hussain Alameeri, Deputy Assistant Secretary for Health Regulation Sector, Ministry of Health and Protection, UAE. – Photo provided Posted: Sun, Nov 21, 2021, 6:12 PM Last update: Sun, Nov 21, 2021, 6:15 PM The UAE has stepped up efforts to eliminate fake drugs […]]]>

Avoid buying drugs or supplements online, health ministry official warns



Dr Amin Hussain Alameeri, Deputy Assistant Secretary for Health Regulation Sector, Ministry of Health and Protection, UAE. – Photo provided

Posted: Sun, Nov 21, 2021, 6:12 PM

Last update: Sun, Nov 21, 2021, 6:15 PM

The UAE has stepped up efforts to eliminate fake drugs and medical products from reaching consumers amid the pandemic, a senior government official said on Sunday.

UAE has taken tough action against fraudulent companies selling fake Covid-19 vaccines and drugs on the internet and social media platforms, said Dr Amin Hussain Alameeri, Deputy Under Secretary for the Regulatory Sector Department of Health at the UAE Ministry of Health and Protection.

“According to data provided by the World Health Organization (WHO), at least 90% of online pharmaceuticals in the world sell substandard medical or SF products. Globally, at least 100,000 to 1 million people die each year from SF products. said Alameeri. In addition, 50% of illicit drug purchases are made online.

Read also :

He explained, “During the pandemic situation, many companies tried to sell fake vaccines and Covid-19 drugs online, including the United Arab Emirates.”

According to reports published by the United States Food and Drug Administration and Interpol in Europe, numerous shipments containing fake drugs were seized. At least 200 illicit online traders of counterfeit drugs have also been shut down around the world, Alameeri said.

The official called on UAE nationals and residents to avoid purchasing drugs and supplements online. “This is an illicit trade. Avoid buying drugs through social networks. Instead, focus on the authorized government and private pharmacies that are spread across our beautiful country,” he added.

The official spoke to Khaleej Times on the sidelines of the Fourth International Conference on Falsified and Substantial Medicines at the Dubai Exhibition Center, Expo 2020, on November 21.

Meanwhile, Rogério Gaspar, director of the World Health Organization’s regulatory and prequalification department, said collaborative efforts between countries are imperative to tackle the threat of SF drugs and ensure that those in countries the poorest do not buy them. In some parts of Africa, more than 30 percent of drugs sold are substandard or falsified products.

UAE is home to 91 international pharmaceutical logistics centers

The United Arab Emirates is a vital link in the trade of drugs and medical products to at least 42 neighboring countries. “At least 91 pharmaceutical companies have their regional offices and logistics centers located in Dubai. With the presence of these companies, drugs and drugs imported and re-exported to these 42 countries,” said Dr Alameeri.

The UAE plays a crucial role in ensuring that only the highest quality products are imported and exported to these 42 countries and other countries in need. Amid the pandemic, 2,062 tons of medical supplies, including PCR test kits and 2,110 ventilators, were shipped to countries in need during the pandemic. United Arab Emirates, ”Alameeri said.

“We have a long history of trying to tackle falsified medicines entering the markets of the United Arab Emirates. We have many technologies and, with the support of international agencies such as the WHO and other agencies, we are protecting healthcare. health and medical well-being of communities in these 42 countries, ”he added.

Strategic measures to combat counterfeit medicines

From March 3 to 10, 2020, Interpol and participating government authorities seized 4.4 million units of illicit pharmaceuticals worldwide.

Citing a report from Interpol, Alameeri said that antibiotics, erectile dysfunction pills, cancer and diabetes drugs, and hypnotics and sedatives are among the most commonly found counterfeit medical products on the market.

The UAE is implementing a five-pronged strategic preventive measure, working with law enforcement, in its attempt to combat bogus entry into the market, Dr Alameeri said. First, it educates communities about the harms of consuming such products through medical conferences and mass media.

Second, MoHAP encourages collaboration with stakeholders in drug control communities such as the Dubai Health Authority, the Abu Dhabi Department of Health, the Ministry of Justice, the Federal Customs Authority and the Public minister. The third and fourth components include building capacity for quality control and surveillance and monitoring.

“Plus, every drug package is tracked from manufacturer to patient using an app called Tatmeen,” Alameeri said. Tatmeen is a highly advanced tracking and traceability platform for pharmaceutical and medical products initiated by MoHAP.

What is the impact of consuming falsified medicines?

> Loss of income due to prolonged illness or death

> Lost productivity costs for patients and households when seeking additional medical care

> Lack of social mobility and increase in poverty

> Economic loss for patients, their families, healthcare systems and industry

> Waste of human effort and financial expenditure throughout the health system

> Increased burden on healthcare professionals, national drug regulatory authorities, law enforcement and criminal justice systems

> Loss of confidence in the health system

> Increased mortality and morbidity due to hazardous contaminants


Source link

]]>
SK Inc. could invest in the Center for Breakthrough Medicines https://fabricadecosas.org/sk-inc-could-invest-in-the-center-for-breakthrough-medicines/ Tue, 16 Nov 2021 08:31:05 +0000 https://fabricadecosas.org/sk-inc-could-invest-in-the-center-for-breakthrough-medicines/ SK Inc. head office in Jongno district, central Seoul [NEWS1] SK Inc. is in final talks to invest in the Center for Breakthrough Medicines (CBM), a Philadelphia-based gene and cell therapy company, to strengthen its presence in the global contract manufacturing organization (CMO) market. The deal will likely be done this year, although no specific […]]]>

SK Inc. head office in Jongno district, central Seoul [NEWS1]

SK Inc. is in final talks to invest in the Center for Breakthrough Medicines (CBM), a Philadelphia-based gene and cell therapy company, to strengthen its presence in the global contract manufacturing organization (CMO) market.

The deal will likely be done this year, although no specific details about its size have been disclosed, according to Lee Dong-hoon, director of SK Inc.’s Bio Investment Center, who chaired Tuesday’s online conference.

“CBM is one of the world’s leading contract development and manufacturing organizations [CDMO] players specializing in gene and cell therapy, which could create synergy effects with our CMO company, SK Pharmteco, ”Lee said at the conference.

Founded in 2019 as a wholly owned subsidiary of SK Inc., SK Pharmteco is headquartered in Sacramento, California, and is engaged in the contract manufacturing of pharmaceutical products. Earlier this year, SK Inc. revealed its intention to become one of the top five CMO companies specializing in gene and cell therapy, referring to biological treatments that alter cellular and genetic information to cure disease.

SK Inc. and CBM aim to build a 700,000 square foot gene and cell therapy manufacturing plant by 2025 and hire 2,000 employees.

“Unlike Samsung Biologics and Celltrion, the two main Korean biopharmaceutical companies, SK Pharmteco stands out in three areas,” said Lee. “It is more focused on the US market, next generation drugs, and is looking to grow through mergers and acquisitions.”

The investment plan comes eight months after SK Inc. acquired 70 percent of Yposkesi, Corbeil Essonnes, a French CDMO company also specializing in gene and cell therapy.

Gene and cell therapies are a rapidly growing market around the world and are used in the treatment of many diseases, according to SK Inc.

At present, antibody treatments occupy the bulk of the market, but according to a report by Deloitte cited by SK Inc., the gene and cell therapy market is expected to overtake it growing by 25% per year by 2025. .

Asked about plans for an initial SK Pharmteco public offering, Lee said the company was fully ready but was looking for the best time.

“We’re still ready to go public, it could be next year or two years later,” Lee said. “But we still have little to do with making decisions, such as how to use the big funding for the growth of the business, as well as for the benefit of our shareholders.”

BY SARAH CHEA [chea.sarah@joongang.co.kr]


Source link

]]>
REVOLUTION MEDICINES, INC. : Results of operations and financial situation, financial statements and exhibits (form 8-K) https://fabricadecosas.org/revolution-medicines-inc-results-of-operations-and-financial-situation-financial-statements-and-exhibits-form-8-k/ Wed, 10 Nov 2021 21:09:44 +0000 https://fabricadecosas.org/revolution-medicines-inc-results-of-operations-and-financial-situation-financial-statements-and-exhibits-form-8-k/ Item 2.02 Operating results and financial position. At November 10, 2021, Drug Revolution, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2021. The full text of the press release issued in connection with the announcement is provided as Exhibit 99.1 of this current report on Form 8-K. The information in […]]]>

Item 2.02 Operating results and financial position.

At November 10, 2021, Drug Revolution, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2021. The full text of the press release issued in connection with the announcement is provided as Exhibit 99.1 of this current report on Form 8-K.

The information in this Section 2.02 and Attachment 99.1 is provided and will not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the requirements of this section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except in the cases expressly stated by specific reference. in such a folder.

Item 9.01 Financial statements and supporting documents.



(d) Exhibits



Exhibit
  No.       Description

99.1          Press Release, dated November 10, 2021.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

————————————————– ——————————-

© Edgar online, source Previews


Source link

]]>
Drug Safety Week: Making vaccines better for everyone https://fabricadecosas.org/drug-safety-week-making-vaccines-better-for-everyone/ Fri, 05 Nov 2021 17:20:00 +0000 https://fabricadecosas.org/drug-safety-week-making-vaccines-better-for-everyone/ The Caribbean Regulatory System (CRS) of the Caribbean Public Health Agency (CARPHA), in collaboration with the Pan American Health Organization / World Health Organization (PAHO / WHO), launches a week-a long social media campaign to promote the importance of reporting suspected side effects after vaccination to CRS or national reporting systems. Taking place from 1–7 […]]]>

The Caribbean Regulatory System (CRS) of the Caribbean Public Health Agency (CARPHA), in collaboration with the Pan American Health Organization / World Health Organization (PAHO / WHO), launches a week-a long social media campaign to promote the importance of reporting suspected side effects after vaccination to CRS or national reporting systems.

Taking place from 1–7 November 2021, the sixth #MedSafetyWeek social media campaign will focus on vaccines. Pharmaceutical agencies in 64 countries will encourage health professionals, national immunization program staff, as well as patients and their caregivers and families, to report problems with vaccines, including COVID-19 injections.

Vaccines are among the most important advances in medicine, saving millions of lives each year and have proven to be the best method to protect people against infectious diseases. However, as with all medicines, side effects can occur.

According to Mr. Dean Chambliss, PAHO Subregional Program Director, Caribbean, “This campaign comes at a critical time when millions of people are being vaccinated against COVID-19. Vaccine safety begins with the timely detection and reporting of adverse events after vaccination. It is important to report suspected adverse events of vaccines and by extension all drugs. Every report counts, but to have an impact, countries must assess this information and regularly share security updates with the international community. “

In August 2021, CARPHA launched its Post-Vaccine Adverse Event Reporting (AEFI) online form which can be used for any vaccine, including newer COVID-19 vaccines. Dr. Joy St. John, Executive Director of CARPHA, said: “Reporting an adverse reaction after vaccination does not mean that the event was caused by the vaccine or that the person who administered the vaccine did. an error, but it is a part to help national authorities identify events that may require further investigation. Information from surveys and data analyzes will help Member States to identify the types of reactions people experience and any additional monitoring or regulatory action that may be required. “

Reporting side effects that last more than three days, and those that get people to see a doctor is an important part of verifying and ensuring that approved vaccines remain safe when used in larger populations. Health workers are encouraged to use relevant vaccine information from trusted sources to guide patients, parents and caregivers.

For more information on COVID-19 vaccines:


Source link

]]>
REVOLUTION MEDICINES, INC. : conclusion of a material definitive agreement, creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of a holder (form 8-K) https://fabricadecosas.org/revolution-medicines-inc-conclusion-of-a-material-definitive-agreement-creation-of-a-direct-financial-obligation-or-an-obligation-under-an-off-balance-sheet-arrangement-of-a-holder-form-8-k/ Thu, 04 Nov 2021 20:22:20 +0000 Item 1.01 Conclusion of a Material Definitive Agreement. Effective from November 1, 2021, Drug Revolution, Inc. (the “Company”) has entered into a third amendment to the lease (the “third amendment”) with HCP LS Redwood City, LLC (the “Lessor”), which modifies that certain dated leases January 15, 2015 with the Landlord, as twice amended (the “Lease”), […]]]>

Item 1.01 Conclusion of a Material Definitive Agreement.

Effective from November 1, 2021, Drug Revolution, Inc. (the “Company”) has entered into a third amendment to the lease (the “third amendment”) with HCP LS Redwood City, LLC (the “Lessor”), which modifies that certain dated leases
January 15, 2015 with the Landlord, as twice amended (the “Lease”), to lease an additional 41,445 square feet (the “800 Building”) of office, laboratory and research and development space located at 800 Saginaw Drive, Redwood City, California (as well as the premises previously rented under the Lease, the “Premises”), and to extend the term of the lease of the part of the Premises located at 700 Saginaw Drive, Redwood City, California (the “Building 700”) and 300 Saginaw Drive, Redwood City, California (the “Building 300”). The Company previously entered into a second amendment to the lease on April 17, 2020 (the “Second Amendment”), to lease an additional 19,484 square feet of office, laboratory, and research and development space for Building 300.

Under the Third Amendment, the term of the lease for the part of the premises located in building 800 should begin on November 7, 2021 and expire on November 30, 2033, and the lease expiry dates for Building 700 and Building 300 have been extended by December 31, 2030 To November 30, 2033 (the “Lease Extension Period”). The Company has the option of extending the term of the lease for all the Premises for an additional ten years beyond the end of the Lease Extension Period (the “Option Term”).

The annual base rent for the rental of the part of the premises located in building 800 is approximately $ 2.685 million up to November 30, 2022, after which the annual base rent will increase by approximately 3.5% in each subsequent year of the lease term. The annual base rent for Building 300 and Building 700 remains unchanged until the expiration date of the previous lease under the Second Amendment. At the start of the lease extension period, the annual base rent for building 700 will be approximately
$ 3.565 million and will then increase by 3.5% per year on each May 1
during the lease extension period, and the annual base rent for building 300 will be approximately $ 1.715 million and will then increase by 3.5% per year on each January 1st during the lease extension period. The Company will also continue to be responsible for the payment of its pro rata share of operating expenses and taxes for the Premises.

The third amendment also provides for a two-month reduction in the basic monthly rent for building 800, from December 1, 2021 through January 30, 2022. Under the Third Amendment, the lease continues to provide for an annual base rent during the term of the option, if any, to be calculated based on a fair market rental rate as determined in the lease.

The foregoing description of material terms of the Third Amendment is not intended to be complete and is subject to, and is qualified in its entirety by, a reference to the Third Amendment, which will be filed as an attachment to the Company’s Quarterly Report. on form 10-Q for the quarterly period ending
September 30, 2021.

Item 2.03 Creation of a Direct Financial Obligation or Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

The information included in Item 1.01 of this current report on Form 8-K is incorporated in this Item 2.03 by reference.

————————————————– ——————————

© Edgar online, source Previews


Source link

]]>
Drones will soon deliver medicine to elderly Ghanaians at their homes – information minister reveals | Health https://fabricadecosas.org/drones-will-soon-deliver-medicine-to-elderly-ghanaians-at-their-homes-information-minister-reveals-health/ Thu, 04 Nov 2021 15:16:20 +0000 https://fabricadecosas.org/drones-will-soon-deliver-medicine-to-elderly-ghanaians-at-their-homes-information-minister-reveals-health/ Information Minister Kojo Oppong Nkrumah has revealed that drones will soon be used to deliver medicine to Ghanaians at homes. Elderly Ghanaians will no longer have to worry about shopping for drugs, he said, as the government is launching a new program in partnership with Zipline to ensure their drugs are delivered to them in […]]]>

Information Minister Kojo Oppong Nkrumah has revealed that drones will soon be used to deliver medicine to Ghanaians at homes.

Elderly Ghanaians will no longer have to worry about shopping for drugs, he said, as the government is launching a new program in partnership with Zipline to ensure their drugs are delivered to them in the comfort of their own homes.

He made the revelation by elucidating Vice President Dr. Mahamudu Bawumia’s public lecture held at Ashesi University on Tuesday evening on the theme “Transforming an Economy Through Digitization: The Story of Ghana”.

Dr Bawumia praised the government’s efforts to make healthcare sufficiently accessible to Ghanaians, especially those in rural areas, through the Zipline drone service aimed at delivering medical supplies to patients faster.

The vice president praised the government’s achievements since it launched the drone healthcare delivery service.

Ghana was the second African country after Rwanda to implement the delivery of medical supplies by drones. There are currently four Zipline distribution centers … and those four centers deliver an average of 100 flights per day. In December, we will add two more centers … ”, he said.

He added; ” Ghana is the largest medical drone delivery service in the world … What’s even more impressive is that the drone centers are 100% occupied by talented young Ghanaians [100%]. It’s the flight operators and everything and it’s really a sight to see when you see them in action. ”

Speaking in an interview on Peace FM Thursday morning ” Kokrokoo ” program, Hon. Oppong Nkrumah also highlighted the benefits of the drone healthcare delivery service, pointing out that drones were used to transport blood samples to medical centers during the COVID-19 outbreak.

He further said that drones have also been of great benefit to rural communities by providing emergency health services to residents.

“Each day, the four Zipline drone centers perform an average of 400 flights per day”, he said.

To advance the health sector with the help of technology, the medical drone service will be upgraded to provide individualized services, the minister noted, stressing “if an elderly person is at home and needs medication but cannot move, now due to the property’s digital addressing system we are opening a platform that if he can buy his drugs on the Zipline platform a drone will deliver the drugs to the elderly in his yard ”.

Source: Ameyaw Adu Gyamfi / Peacefmonline.com / Ghana

Disclaimer: The opinions expressed here are those of the authors and do not reflect those of Peacefmonline.com. Peacefmonline.com accepts no legal or other responsibility for the accuracy of their content. Please report any inappropriate content to us and we will evaluate it as a priority.

Featured Video


Source link

]]>
Personalized Medicines Market Analysis and Forecast with Key Focus on the World 2021-2027 https://fabricadecosas.org/personalized-medicines-market-analysis-and-forecast-with-key-focus-on-the-world-2021-2027/ Wed, 03 Nov 2021 09:15:12 +0000 https://fabricadecosas.org/personalized-medicines-market-analysis-and-forecast-with-key-focus-on-the-world-2021-2027/ New Jersey, United States, – Market Research Intellect recently released a new report titled Global Personalized Medicines Market Outlook 2021. The report has been developed using primary as well as secondary research methodologies, which provide precise and precise understanding of the Personalized Medicines Market. Analysts have used a top-down and bottom-up approach to assess the […]]]>

New Jersey, United States, – Market Research Intellect recently released a new report titled Global Personalized Medicines Market Outlook 2021. The report has been developed using primary as well as secondary research methodologies, which provide precise and precise understanding of the Personalized Medicines Market. Analysts have used a top-down and bottom-up approach to assess the segments and provide a fair assessment of their impact on the global foldable phone market. The report provides a market overview, which briefly describes the market situation and key segments. It also mentions the major players present in the global foldable phone market.

Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=189993

The Personalized Drugs Market share report divides the market by volume and value based on major manufacturer, application, product type, and geography. The report gives an accurate analysis of the Personalized Drugs products on the basis of revenue, sales volume, price, cost, and gross margin which is helpful in making decisions for establishing the industry.

The Personalized Medicines report was developed after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological and political status of the region in question. Analysts studied revenue, production, and manufacturer data in each region. This section analyzes the revenue and volume by region for the forecast period 2015 to 2024. These analyzes will help the reader to understand the potential value of investing in a particular region.

Overview of the impact of Covid-19 on the personalized medicine market:

The emergence of COVID-19 has crippled the world. We understand that this health crisis has had an unprecedented impact on companies in the industry. But it will also pass. Increased support from governments and businesses can help fight this highly contagious disease. There are industries that are struggling and there are industries that are thriving. Overall, almost all sectors are expected to be affected by pandemics. We are committed to ensuring the sustainability and growth of your business during the Covid-19 epidemic. Our experience and expertise will help us prepare for the future by providing industry-wide impact analysis of coronavirus outbreaks.

The main players covered by the personalized medicines markets:

    • 3g Biotech
    • Quest Diagnosis
    • Laboratory Society of America
    • Abbott
    • Diary Nv
    • Asuragen Inc
    • Becton Dickinson
    • Cardiodx Inc.
    • Basic medicine
    • Qiagen
    • Siemens Healthcare
    • Amgen
    • Bristol-myers Squibb
    • Ge Health
    • Pfizer
    • Sanofi
    • 23andme
    • Illumina

Segmentation of the personalized medicines market:

The Personalized Drugs market is split by Type and by Application. For the period 2021-2028, the cross-industry growth provides accurate calculations and sales forecast by type and application in terms of volume and value. This analysis can help you grow your business by targeting qualified niche markets.

Market breakdown of personalized medicines by type:

    • Afternoon diagnosis
    • PM Therapeutic
    • Personalized medical care
    • Personalized nutrition and well-being

Personalized Medicines Market Split By Application:

    • Hospitals Pharmacies
    • Retail pharmacies
    • Dietetic care centers
    • Others

Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=189993

Scope of the Personalized Drugs Market Report

Report attribute Details
Market size available for years 2021 – 2028
Reference year considered 2021
Historical data 2015 – 2019
Forecast period 2021 – 2028
Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
Covered segments Types, applications, end users, etc.
Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free customization of the report (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
Price and purchase options Take advantage of personalized shopping options to meet your exact research needs. Explore purchasing options

Regional Market Analysis Personalized Medicines can be represented as follows:

Each regional Personalized Medicine sector is carefully studied to understand its current and future growth scenarios. It helps the players to strengthen their position. Use market research to gain a better perspective and understanding of the market and target audience and to ensure you stay ahead of the competition.

Geographically, the global Personalized Medicines market is segmented as follows:

    • North America includes the United States, Canada and Mexico
    • Europe includes Germany, France, UK, Italy, Spain
    • South America includes Colombia, Argentina, Nigeria and Chile
    • Asia-Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

For more information or a query or customization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-personalized-medicines-market-size-and-forecast/

Visualize the Custom Medicines Market Using Verified Market Intelligence: –

Verified Market Intelligence is our BI platform for telling the story of this market. VMI provides in-depth predictive trends and accurate insights into over 20,000 emerging and niche markets to help you make key revenue impact decisions for a bright future. VMI provides a comprehensive overview and global competitive landscape by regions, countries and segments, as well as as key players in your market. Present your market reports and findings with built-in presentation capabilities, delivering over 70% of time and resources to investors, sales and marketing, R&D and product development. VMI supports data delivery in interactive Excel and PDF formats and provides over 15 key market indicators for your market.

Visualize the personalized drug market using VMI @ https://www.marketresearchintellect.com/mri-intelligence/

The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analysis report is useful for all new entrants and new entrants as they design their business strategies. This report covers the production, revenue, market share and growth rate of the Personalized Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. . Historical distribution data for Personalized Medicines from 2016 to 2020 and forecasts until 2021-2029.

About Us: Market Research Intelligence

Market Research Intellect provides syndicated and personalized research reports to clients across various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

Contact us:
Mr. Edwyne Fernandes
United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768

Website: –https://www.marketresearchintellect.com/


Source link

]]>
Congestive Heart Failure Drugs Market To See Exponential Growth By 2021-2027 https://fabricadecosas.org/congestive-heart-failure-drugs-market-to-see-exponential-growth-by-2021-2027/ Tue, 02 Nov 2021 01:06:08 +0000 https://fabricadecosas.org/congestive-heart-failure-drugs-market-to-see-exponential-growth-by-2021-2027/ New Jersey, United States, – Recently released report titled “(Medicines for Congestive Heart Failure Market)” by Market Research Intellect highlights industry dynamics and current and future trends that play a key role in determining business expansion . The report also highlights the main drivers and constraints impacting growth. For a holistic understanding, professionals examined the […]]]>

New Jersey, United States, – Recently released report titled “(Medicines for Congestive Heart Failure Market)” by Market Research Intellect highlights industry dynamics and current and future trends that play a key role in determining business expansion . The report also highlights the main drivers and constraints impacting growth. For a holistic understanding, professionals examined the regulatory scenario, market entry strategies, industry best practices, pricing strategy, technology landscape, and consumption, sales and demand outlook. Annual growth estimates have also been included to provide users with accurate statistics and facts. This report will give readers a broader and more transparent picture of the overall scenario.

Covid-19 impact outlook

This section of the report reveals the impact of the covid pandemic on businesses around the world. The effect on manufacturing activities, production, demand, supply chain and logistics management and distribution networks has been described in this report. Analysts have highlighted the measures or strategies companies are adopting to combat the impact of covid-19. In addition, they identified the key opportunities that emerge after COVID-19. This will help players capitalize on opportunities to recoup losses and stabilize their business.

Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=216059

The Congestive Heart Failure Drugs market share report divides the market in volume and value based on major manufacturer, application, product type, and geography. The report gives an accurate analysis of the Congestive Heart Failure Drugs products based on sales revenue, sales volume, price, cost and gross margin, which is useful for making decisions for establishing industry.

The Medicines for Congestive Heart Failure report was developed after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological and political status of the region in question. Analysts studied revenue, production, and manufacturer data in each region. This section analyzes the revenue and volume by region for the forecast period 2015 to 2024. These analyzes will help the reader to understand the potential value of investing in a particular region.

Overview of the impact of Covid-19 on the Congestive Heart Failure Drugs market:

The emergence of COVID-19 has crippled the world. We understand that this health crisis has had an unprecedented impact on companies in the industry. But it will also pass. Increased support from governments and businesses can help fight this highly contagious disease. There are industries that are struggling and there are industries that are thriving. Overall, almost all sectors are expected to be affected by pandemics. We are committed to ensuring the sustainability and growth of your business during the Covid-19 epidemic. Our experience and expertise will help us prepare for the future by providing industry-wide impact analysis of coronavirus outbreaks.

The Major Players Covered By The Congestive Heart Failure Drugs Markets:

    • Novartis
    • Pfizer
    • Astrazeneca
    • Hikma
    • Gsk
    • Suits you
    • Cipla
    • Merck
    • Amgen
    • rock
    • Sun Pharma
    • Mylan
    • Sanofi
    • Bristol-myers Squibb
    • Johnson and Johnson
    • Bayer

Congestive Heart Failure Drugs Market Segmentation:

The Congestive Heart Failure Drugs market is split by Type and by Application. For the period 2021-2028, Intersectoral Growth provides accurate sales calculations and forecasts by type and application in terms of volume and value. This analysis can help you grow your business by targeting qualified niche markets.

Congestive Heart Failure Drugs Market Split By Type:

Congestive Heart Failure Drugs Market Split By Application:

Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=216059

Scope of the Congestive Heart Failure Drugs Market Report

Report attribute Details
Market size available for years 2021 – 2028
Reference year considered 2021
Historical data 2015 – 2019
Forecast period 2021 – 2028
Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
Covered segments Types, applications, end users, etc.
Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free customization of the report (equivalent to up to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
Price and purchase options Take advantage of personalized shopping options to meet your exact research needs. Explore purchasing options

Regional Market Analysis Congestive Heart Failure Drugs can be represented as follows:

Each regional Congestive Heart Failure Drugs sector is carefully studied to understand its current and future growth scenarios. It helps the players to strengthen their position. Use market research to gain a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

Based on geography, the global congestive heart failure drugs market has segmented as follows:

    • North America includes the United States, Canada and Mexico
    • Europe includes Germany, France, UK, Italy, Spain
    • South America includes Colombia, Argentina, Nigeria and Chile
    • Asia-Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

For more information or a query or customization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-medicines-for-congestive-heart-failure-market-size-and-forcast/

Visualize Drugs For Congestive Heart Failure Market Using Verified Market Intelligence: –

Verified Market Intelligence is our BI platform to tell the story of this market. VMI provides in-depth predictive trends and accurate insights into over 20,000 emerging and niche markets to help you make key revenue impact decisions for a bright future. VMI provides a comprehensive overview and global competitive landscape by regions, countries and segments, as well as as key players in your market. Present your market reports and findings with built-in presentation capabilities, delivering over 70% of time and resources to investors, sales and marketing, R&D and product development. VMI supports data delivery in interactive Excel and PDF formats and provides over 15 key market indicators for your market.

Visualize Drugs For Congestive Heart Failure Market Using VMI @ https: //www.marketresearchintellect.com/mri-intelligence/

The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analysis report is useful for all new entrants and new entrants as they design their business strategies. This report covers the production, revenue, market share and growth rate of the Congestive Heart Failure Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical congestive heart failure drug distribution data from 2016 to 2020 and forecast to 2021-2029.

About Us: Market Research Intelligence

Market Research Intellect provides syndicated and personalized research reports to clients across various industries and organizations, in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

Contact us:
Mr. Edwyne Fernandes
United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768

Website: –https://www.marketresearchintellect.com/


Source link

]]>